AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

AMRN · NASDAQ · Drug Manufacturers - General

Amarin (ADR)

Commercializes icosapent ethyl for cardiovascular care through Vascepa and Vazkepa.

$13.97

After-hours close0.00 (0.00%)

At close$13.97(−0.71%)

Something off on this page? Send us feedback.

Profile

Amarin Corporation plcAMRNHealth Care

Commercializes icosapent ethyl as Vascepa in the United States and Vazkepa abroad. The company relies heavily on the product, selling directly in the United States and through international partners.

Vascepa and Vazkepa are brands for icosapent ethyl, the cardiovascular therapy at the center of the business. Vascepa began with an FDA-approved use for adults with severe hypertriglyceridemia and later gained a defined cardiovascular-risk-reduction use.

Sales combine a direct U.S. operation with indirect distribution through international partners, including European and other markets. The company is not built around a broad drug-discovery portfolio.

Most revenue comes from Vascepa, keeping its economics substantially tied to one product. U.S. sales operate alongside generic competition after a court invalidated several patents protecting the original U.S. use.

Company facts

CEOAaron D. Berg

ListedApr 1, 1993

ExchangeNASDAQ

HeadquartersDublin, Ireland

CountryIreland

Employees275

CIK0000897448

ISINUS0231114044

Key statistics

Market cap$288.9M

EPS (ttm)−$1.43

P/E (ttm)−9.78

ROE-6.0%

P/B0.6557

P/S1.55

Dividend yield—

Beta0.53vs XLV 0.26

Year to date +1.8% · Average volume (30d) 73.9K

Analysts

Price target, next 12 months$2.00−85.7%Median of 18 analysts · vs the Aug 28 close

ConsensusHold3 of 18 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $13.97

High$3.00−78.5%

Median$2.00−85.7%

Low$1.50−89.3%

12 months agoNowIn 12 months

Latest analyst notes

No analyst notes in the last 24 months.

Earnings

EPS

Estimate−$0.10

ReportedDue Nov 4, 2026

Revenue

Estimate$43.8M

ReportedDue Nov 4, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Jul 29, 2026Q2 FY26	−$0.01	−$0.02	−100.0%	$44.6M	$42.2M	−5.3%	+1.51%
Apr 29, 2026Q1 FY26	$0.01	−$0.09	−1,000.0%	$43.8M	$45.1M	+3.1%	−2.52%
Feb 25, 2026Q4 FY25	$0.07	$0.01	−85.7%	$50.6M	$49.2M	−2.8%	+0.50%
Oct 29, 2025Q3 FY25	$0.08	$0.01	−87.5%	$43.1M	$49.7M	+15.2%	−2.44%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$42.0M	$72.7M	$49.7M	$49.1M	$45.1M	$42.2M
Gross profit	$25.1M	$50.4M	$22.2M	$22.4M	$17.8M	$15.0M
Operating income	−$16.8M	−$16.0M	−$11.1M	−$2.3M	−$8.0M	−$12.0M
Net income	−$15.7M	−$14.1M	−$7.7M	−$1.2M	−$10.5M	−$7.7M
Diluted EPS	−$0.76	−$0.68	−$0.37	−$0.06	−$0.60	−$0.40
Gross margin	59.8%	69.2%	44.7%	45.6%	39.4%	35.5%
Operating margin	-39.9%	-22.0%	-22.4%	-4.6%	-17.8%	-28.4%

Fiscal years (4-quarter sums)FY21 $583.2M · FY22 $369.2M · FY23 $306.9M · FY24 $228.7M · FY25 $213.6M

Revenue by product · Q2 FY26

Product$39.1M · 93%

Licensing And Royalty$3.1M · 7%

Revenue by geography · Q2 FY26

United States$32.2M · 86%

Europe$5.4M · 14%

Balance sheet, Jun 30, 2026Cash & short-term investments $314.6M · Total debt $5.3M · Total assets $624.4M · Shareholders' equity $443.6M

Dividends

No dividends on record.

Ownership

Institutions 22.53%Insiders —

Shares outstanding 20.68M · Float —

Insiders — filings are in the shares behind the receipt.

This listing is a depositary receipt and the Form 4 positions here are filed in the shares behind it, a different unit from the share count and in a ratio the filings never state, so no insider percentage is shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Sarissa Capital Management LP	1.67M	8.09%	13F	Aug 14, 2026
Acadian Asset Management LLC	721.0K	3.49%	13F	Aug 13, 2026
Kynam Capital Management, LP	533.0K	2.58%	13F	Aug 14, 2026
Morgan Stanley	223.6K	1.08%	13F	Aug 13, 2026
Waterfront Wealth Inc.	213.9K	1.03%	13F	Jul 30, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.